Tulavi Therapeutics Achieves Breakthrough Technology Designation for Innovative Synthetic Implants

Tulavi Therapeutics Receives Breakthrough Technology Designation

In a significant advancement for medical technology, Tulavi Therapeutics, based in Los Gatos, California, has recently been awarded a national group purchasing agreement and the esteemed Breakthrough Technology Designation for its innovative product, the allay™ Hydrogel Cap. This designation, granted in collaboration with Premier, Inc., is a testament to the potential impact of this synthetic implant on patient care and operational efficiency in medical settings.

Since its effective date of September 15, 2026, this new agreement allows members of Premier to benefit from specially negotiated pricing and terms for the allay™ Hydrogel Cap. This device is recognized as the first fully resorbable, in situ forming medical device specifically designed to mitigate the risk of symptomatic neuroma formation. The designation awarded by Premier aims to highlight technologies that significantly enhance patient safety and clinical outcomes.

Revolutionizing Peripheral Nerve Surgery

As stated by Tulavi’s CEO, Josh Vose, “We’re extraordinarily proud to reach this milestone as we work to redefine what's possible in peripheral nerve surgery.” This agreement represents a crucial step forward, potentially improving access to the allay™ Hydrogel Cap for a wider patient demographic, healthcare providers, and organizations focused on innovative surgical practices.

Every year, approximately 600,000 amputations and 1.9 million peripheral nerve surgeries are conducted in the United States. When a peripheral nerve is damaged, whether due to trauma or surgical procedures, it can lead to abnormal growth of axons, forming disorganized structures known as neuromas. These can lead to debilitating pain, characterized by hypersensitivity or stabbing sensations, significantly affecting the quality of life for patients. Neuromas are often a major source of chronic residual limb pain and can complicate the use of prosthetics.

The unique allay™ Hydrogel Cap relies on a proprietary hydrogel platform that has been safely utilized in over 10 million patients worldwide. This device is engineered to specifically support nerve healing by acting as a conforming barrier to the injured nerve, while also reducing the risks associated with symptomatic neuroma formation. Once applied, the hydrogel cap remains in position for approximately eight months, providing necessary protection during the critical phase of neuroma development.

Commitment to Improve Patient Outcomes

Premier is recognized as a leader in technology-driven healthcare solutions, bridging gaps between providers, suppliers, and payers to enhance the healthcare experience. Their dedication to improving the efficiency and safety of healthcare practices aligns seamlessly with Tulavi’s mission. Tulavi Therapeutics aims to transform the landscape of peripheral nerve surgery through its innovative biomaterial products, ensuring better patient outcomes and setting a new standard for care.

With the breakthrough designation and its commitment to advancing surgical solutions, Tulavi Therapeutics is poised to Make a remarkable difference in the field of nerve repair and protection in the relatively short span of its evolving technology.

References

1. Rivera, J. A., et al. (2024). Archives of Rehabilitation Research and Clinical Translation.
2. Döring, K., et al. (2021). Clinical Orthop Relat Res.
3. Yang, H., et al. (2023). Front Neurol.
4. Dellon, A. L. (2001). Journal of the American Society for Surgery of the Hand.

In summary, if you or someone you know is dealing with the complications of peripheral nerve injuries, the allay™ Hydrogel Cap may represent an encouraging development in surgical interventions to help manage nerve healing more effectively.